S-1: Farlong Holding Files S-1 for IPO Amidst Losses

Farlong Holding Corporation, a science-driven healthcare and wellness company, has filed an S-1 registration statement for its initial public offering, seeking capital to fund operations and growth despite recurring losses and a going concern warning.

Summary

• Farlong Holding Corporation is pursuing an Initial Public Offering (IPO) to raise capital for general corporate purposes, R&D, marketing, infrastructure upgrades, and international expansion.
• The company has experienced recurring losses from operations and negative cash flows since 2022, with a net loss of approximately $1.9 million for the nine months ended June 30, 2025, and an accumulated deficit of $6.0 million, raising substantial doubt about its ability to continue as a going concern.
• Revenue for the nine months ended June 30, 2025, increased by 15.07% to approximately $0.6 million, driven by a strategic shift to BioPrecision formulations and new OEM customer relationships.
• Gross profit decreased by 16.44% to approximately $0.3 million for the nine months ended June 30, 2025, with gross margin falling to 55.80% from 76.84% in the prior year, primarily due to lower margins on the new BioPrecision product line.
• Selling expenses surged by 266.16% to approximately $0.4 million, mainly due to initial marketing efforts on TikTok for the BioPrecision product line launch.
• Research and development expenses increased to approximately $0.1 million for the nine months ended June 30, 2025, due to new clinical trials with City of Hope.
• The DirecTCM platform, launched in May 2025, has approximately 30,000 pre-registered healthcare providers but only 75 active users as of June 30, 2025, and generated immaterial subscription revenue.
• Past clinical trials for Notoginseng, InnerPure, and Breviscapine showed beneficial effects but did not demonstrate statistically significant outcomes and were designed as exploratory studies.
• The company is a 'controlled company' under Nasdaq rules, with Karin Mei Huang holding a significant voting majority post-IPO, though it does not currently intend to rely on related exemptions.
• Farlong relies heavily on third-party contract manufacturers in China for all supplement production, exposing it to U.S. tariffs and trade disputes.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses and a 'going concern' warning. While there's revenue growth and strategic initiatives, the lack of statistically significant clinical trial results and low active user engagement on its key platform (DirecTCM) are major concerns. The IPO is critical for survival and growth, but the underlying financial health and operational risks are substantial.

Positives

• Revenue increased by 15.07% to $0.6 million for the nine months ended June 30, 2025, indicating growth in sales.
• Successful launch of the DirecTCM platform in May 2025, accumulating approximately 30,000 pre-registered healthcare providers by June 30, 2025.
• Strategic restructuring of product lines to emphasize higher-potential BioPrecision formulations, which generated approximately $0.3 million in revenue for the nine months ended June 30, 2025.
• Development of new OEM customer relationships contributed approximately $0.2 million in revenue for the nine months ended June 30, 2025.
• Increased average revenue per wholesale customer by 21.84% to $6,000 and per retail customer by 91.19% to $2,000 for the nine months ended June 30, 2025.
• Ongoing R&D collaborations with City of Hope for White Button Mushroom (anti-cancer/immune modulation), Polygonum Capitatum (anti-diabetes), and Rodgersia Sambucifolia Hemsl (anti-cancer) demonstrate commitment to scientific validation.
• Management team includes executives with over two decades of experience in strategic planning, market development, financial management, and public company compliance.
• The company has adopted a Clawback Policy for erroneously awarded incentive-based compensation, aligning with SEC and Nasdaq rules, and a Whistleblower Protection Policy.

Negatives

• Experienced recurring losses from operations and negative cash flows since 2022, with a net loss of $1,900,073 for the nine months ended June 30, 2025, and an accumulated deficit of $5,984,259.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• Gross profit decreased by 16.44% for the nine months ended June 30, 2025, due to a lower gross margin (30.88%) on the new BioPrecision formulation product line.
• Selling expenses increased by 266.16% to $0.4 million for the nine months ended June 30, 2025, primarily due to initial marketing efforts on TikTok.
• Only 75 out of 30,000 pre-registered healthcare providers on the DirecTCM platform were active as of June 30, 2025, representing only 0.25% activation.
• Subscription revenue from the DirecTCM pilot VIP membership program was immaterial for the nine months ended June 30, 2025.
• Past clinical trials did not demonstrate statistically significant outcomes, limiting their use for strong efficacy claims.
• Identified material weaknesses in internal control over financial reporting, including a lack of formal risk assessment policies and IT-related deficiencies.
• Heavy reliance on a small number of customers and vendors, with ZenLife accounting for 27% of revenue and Kunming Aoqun for 49% of purchases for the nine months ended June 30, 2025.
• Significant reliance on third-party contract manufacturers in China, making the company vulnerable to U.S. tariffs and trade disputes.

Risks

• Significant accumulated deficits and negative cash flows raise substantial doubt about the ability to continue as a going concern.
• Need for additional capital, which may not be available on commercially acceptable terms, if at all, leading to potential dilution or business curtailment.
• Operating results may vary considerably in the future, making forecasting challenging and potentially causing results to fall short of expectations.
• Failure to maintain high-quality standards for products and services could harm business and reputation, leading to recalls, negative publicity, and customer loss.
• Reliance on a small number of customers and vendors, with the loss of any material party adversely affecting operations.
• Difficulty in accurately forecasting customer demand, potentially leading to inability to meet demand or make appropriate planning decisions.
• Dependence on Amazon and TikTok for a significant portion of revenue (15% and 19% respectively for the nine months ended June 30, 2025), with any platform restrictions having a material adverse impact.
• Increases in ingredient costs, long lead times, supply shortages, and changes could disrupt the supply chain and negatively impact financial results.
• Risk of allocating limited resources to less profitable or less successful products or services.
• Potential for inventory spoliation, leading to write-offs and significant charges for obsolete or spoiled inventory.
• Failure to renew current leases or locate desirable alternatives for facilities could materially and adversely affect the business.
• Future need for licenses for third-party technology that may be unavailable or offered on commercially unreasonable terms.
• High costs and uncertainty of litigation may prevent enforcement of intellectual property rights against third parties.
• Struggles to partner for technological advancements and new products/services, impacting competitiveness.
• Use of open-source software could subject proprietary software to general release, hinder product sales, and expose to litigation.
• Exposure to risks associated with credit card and other online payment chargebacks and fraud.
• Risks associated with the return policy and warranty if actual returns or claims exceed estimates.
• Inherent risks in clinical studies, particularly as results have not demonstrated statistical significance, potentially diminishing consumer confidence.
• Dependence on brands (Dr. Herbal Well, Best Doctor Formula), with any failure to maintain, protect, or enhance them adversely affecting the business.
• Sourcing ingredients from foreign suppliers, primarily China, exposes the company to international trade and importation risks, including tariffs and supply chain disruptions.
• Reliance on distributors and health professionals for a substantial portion of sales, over whom there is limited control, potentially harming reputation or sales.
• Reliance on network and mobile infrastructure, with interruptions, delays, or errors in apps or websites (including security flaws) limiting capacity and reducing demand.
• Reliance on independent third-party transportation providers, subject to increased shipping costs and potential inability to deliver on a timely basis.
• Insurance may not fully cover all operational risks, and changes in cost or availability could increase expenses or decrease coverage.
• Disruptions in data and information systems, including cybersecurity risks, could harm reputation and business operations.
• Third parties may claim infringement of their intellectual property rights, leading to significant legal expenses and prevention from promoting products.
• Inability to protect the confidentiality of trade secrets and know-how, harming business and competitive position.
• Inadequate protection of trademarks and trade names, hindering name recognition and market presence.
• Exposure to natural and manmade catastrophic events such as hurricanes, earthquakes, fires, power outages, floods, and terrorism.
• Failure to attract or retain key personnel, including executive officers, senior management, and key employees, could adversely affect ongoing operations and growth.
• Vulnerability to U.S. tariffs, trade disputes, and other disruptions related to U.S.-China trade relations due to reliance on Chinese contract manufacturers.
• Intense competition in the herbal supplement industry from existing and new entrants with greater resources.
• Global economic conditions, including inflation, recession, and tighter credit, could materially and adversely affect business.
• Subject to numerous laws and regulations applicable to the herbal supplement industry, with violations leading to fines, recalls, or operational restrictions.
• Changes in FDA and other regulatory agency policies, or disagreements over product classifications, could delay or increase costs.
• Marketing activities are subject to strict governmental regulation, limiting ability to market or promote products.
• Failure to comply with federal, state, and foreign laws and regulations relating to privacy, data protection, and consumer protection could result in significant liability.
• Potential for allegations, harassment, or other detrimental conduct by third parties, harming reputation and market share.
• No public market for common stock prior to this offering, and inability to resell at or above the IPO price.
• Market price of common stock may be volatile or decline regardless of operating performance.
• Immediate and substantial dilution in the net tangible book value of common stock purchased in this offering.
• Failure to implement and maintain effective internal controls or remediate identified material weaknesses could affect reporting obligations and investor confidence.
• Substantial increased costs as a result of being a public company.
• Inability to continue to satisfy Nasdaq listing requirements could lead to delisting.
• Management has broad discretion over the use of IPO funds, which may not enhance results or stock price.
• As a controlled company, Farlong could elect to rely on corporate governance exemptions, adversely affecting public stockholders.
• As an emerging growth company and smaller reporting company, reduced disclosure requirements may make common stock less attractive to investors.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to small public offering and large insider holdings.
• Authorized preferred stock can be designated by the board without stockholder approval, potentially causing substantial dilution or anti-takeover effects.
• Anti-takeover provisions in corporate documents and Nevada law might discourage, delay, or prevent a change in control.
• Sale of a significant number of shares after lock-up expiration may cause the market price to drop significantly.

Future Outlook

The company intends to expand its DirecTCM platform and product offerings, invest further in technology and R&D, and grow its business through wider e-commerce and retail partnerships, including international expansion into Asian and European markets. It plans to continue developing BioPrecision formulations and funding ongoing studies investigating anti-cancer and anti-diabetes applications. The company expects to incur significant additional expenses as a public company and aims to address material weaknesses in internal controls.

Management Comments

• We are a science-driven healthcare and wellness company pioneering innovative solutions and personalized health approaches.
• Our regulatory objective is limited to marketing our formulations in the United States as dietary supplements, for which FDA approval is neither required nor available.
• We believe the BioPrecision formulation product line has resonated strongly with both healthcare providers and consumers, validating our focus on premium, science-backed supplements.
• We believe our future success depends on our ability to maintain and grow the value of our brands, Dr. Herbal Well and Best Doctor Formula.
• Our management team consists of executives with decades of experiences in financial and corporate management functions.
• We prioritize integrating centuries-old herbal wisdom with modern clinical validation. This framework of combining traditional knowledge + modern R&D fuels product innovation and competitive advantage.
• We are actively funding ongoing studies investigating anti-cancer and anti-diabetes applications.
• We believe the current insurance coverage we maintain is in line with the industry.

Industry Context

The global dietary supplement market is projected to grow from $74.3 billion in 2024 to $170.1 billion by 2034 (9.5% CAGR), driven by rising chronic disorders, busy lifestyles, and consumer awareness. The holistic herbal supplement market is also expanding, expected to reach $421 billion by 2032 (6.87% CAGR from 2022). Farlong's focus on science-driven, plant-based BioPrecision formulations and its DirecTCM platform positions it within these growing segments, aiming to differentiate through personalized health approaches and clinical validation, despite past clinical trials not showing statistical significance. The industry faces increasing competition from established players and new entrants with greater resources.

Comparison to Industry Standards

• The company operates in a rapidly growing industry (global dietary supplement market CAGR of 9.5%, herbal supplement market CAGR of 6.87%), suggesting a favorable market environment for expansion.
• Farlong's strategy of combining traditional herbal knowledge with contemporary scientific techniques and pursuing self-affirmed GRAS conclusions aligns with the industry trend towards natural, plant-based, and clean-label products.
• The DirecTCM platform, with its data-driven recommendations and direct-to-patient delivery, aims to compete with established online supplement ordering platforms like Fullscript, but its current low active user rate (0.25% of pre-registered providers) indicates a significant challenge in market penetration compared to more mature platforms.
• The company's reliance on exploratory clinical studies that have not demonstrated statistical significance for efficacy claims may put it at a disadvantage against competitors who can present more robust, statistically significant clinical evidence, potentially impacting consumer and healthcare provider trust.
• Farlong's significant accumulated deficits and going concern warning are substantially below industry financial health standards, where profitable growth is typically expected from companies seeking public investment.
• The high concentration of revenue from a few customers (e.g., ZenLife 27%) and purchases from a few vendors (e.g., Kunming Aoqun 49%) is a common risk in smaller companies but deviates from the diversified supply chains and customer bases of larger, more stable industry players like Nestle Health Science or Metagenics.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed against Longstar on June 20, 2024, by a former employee alleging $1,222,000 in unpaid compensation from 2016 to 2023. Longstar maintains all wages were paid, and legal counsel believes the likelihood of liability is remote, with no loss contingency recorded.

Related Party Transactions

• Long-term loans from Karin Mei Huang (stockholder): $1,000,000 loan dated September 15, 2024, at 9.5% interest, maturing September 15, 2029. An amendment on March 31, 2025, paused monthly interest payments from April 1, 2025, to March 31, 2026, with deferred interest not accruing additional interest. An additional $1,600,000 loan dated March 25, 2025, at 9.5% interest, maturing March 25, 2030, with monthly interest payments starting March 25, 2026.
• Accounts payable to Kunming Aoqun Bio-Tech Co., Ltd. (related party due to Lihua Zeng, family member of Lipin Zeng, serving as director): $781,668 as of June 30, 2025, and $698,319 as of September 30, 2024, for purchased products. Purchases from Kunming Aoqun accounted for 49% of total purchases for the nine months ended June 30, 2025.
• Accounts payable to Yunnan Panlong Yunhai Pharmaceutical Co., Ltd. (related party due to Lihua Zeng's ownership): $60,441 as of June 30, 2025, and September 30, 2024, for purchased products.
• Rent deposit and rent expenses to Longstar Healthpro Manufacturing Inc. (majority owned by Xinjiang Lixing, a former stockholder of Longstar, which is owned by Lihua Zeng): Rent deposit of $19,500 as of June 30, 2025. Rent expenses of $117,000 for the nine months ended June 30, 2025 and 2024.
• Purchase of inventories from Yunnan Panlong Yunhai Pharmaceutical Trading Co., Ltd (related party) for $23,390 on July 28, 2025.
• Share-for-Share Exchange Agreement on December 27, 2023, where Karin Mei Huang exchanged 100% of Longstar's equity for 40,000,000 shares of Farlong's common stock, making Longstar a wholly-owned subsidiary.
• Gift Receipt Agreement on January 31, 2025, where Karin Mei Huang transferred her 40,000,000 shares of Farlong common stock to KML Family Trust (32,000,000 shares) and KMA Trust (8,000,000 shares) for estate planning purposes.

Stakeholder Impact

• Shareholders: New investors will experience immediate and substantial dilution. Existing shareholders (Karin Mei Huang and family trusts) will retain significant control, potentially limiting influence of public shareholders. The 'going concern' warning and recurring losses pose a high risk of investment loss.
• Employees: The company is expanding its workforce, including sales teams and software engineers, indicating potential job growth. Compensation programs are designed to align with performance, including incentive bonuses. The adoption of a Clawback Policy and Whistleblower Protection Policy impacts executive accountability and employee protection.
• Customers: The strategic shift to BioPrecision formulations and expansion of sales channels (DirecTCM, e-commerce, OEM) aims to provide a wider range of products and improved delivery. However, the low active user rate on DirecTCM and the non-statistically significant clinical trial results might affect customer trust and adoption.
• Suppliers: Continued reliance on a few key suppliers, particularly in China, creates concentration risk. U.S. tariffs and trade disputes could impact supplier relationships and costs, potentially affecting product availability and pricing.
• Creditors: The company relies on debt financing from related parties, and its 'going concern' status indicates a heightened risk for creditors if profitability is not achieved.

Next Steps

• Complete the Initial Public Offering and list common stock on the Nasdaq Capital Market under the symbol AFA.
• Utilize IPO net proceeds for general corporate purposes, R&D, marketing, infrastructure upgrades, and international expansion.
• Continue expansion plans for the DirecTCM platform and product offerings, including widening product availability through e-commerce and retail partnerships.
• Invest further in technology and R&D, including refining supplement recommendation methods and expanding the knowledge library on DirecTCM.
• Continue funding ongoing exploratory clinical studies with City of Hope for White Button Mushroom, Polygonum Capitatum, and Rodgersia Sambucifolia Hemsl.
• Address identified material weaknesses in internal control over financial reporting by hiring qualified accounting personnel and implementing training programs.
• Implement a policy prohibiting hedging transactions for company shares in the future.
• The Audit Committee will review and approve related party transactions to ensure fairness to the company and stockholders.

Key Dates

Recommendation

The S-1 filing reveals a company with significant financial distress, including recurring losses and a 'going concern' warning from its auditors. While the IPO aims to raise capital, the underlying business fundamentals show declining gross margins on new products, a very low active user rate on its flagship platform (DirecTCM), and clinical trial results that are exploratory and lack statistical significance for efficacy. The heavy reliance on Chinese manufacturers and a concentrated customer/vendor base add substantial operational and geopolitical risks. The immediate and substantial dilution for new investors, coupled with the 'controlled company' status, further diminishes the attractiveness of this offering. Given these severe financial and operational red flags, a seasoned investor would likely recommend selling or avoiding this stock.

Keywords

Herbal Supplements, Dietary Supplements, Traditional Chinese Medicine, TCM, BioPrecision, DirecTCM, Health and Wellness, Nutraceuticals, IPO, SEC Filing, S-1, Nasdaq, Clinical Trials, GRAS, e-commerce, Amazon, TikTok, Contract Manufacturing, Supply Chain, Corporate Governance, Risk Management, Financial Reporting